U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07698613) titled 'EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer' on July 07.
Brief Summary: This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection
Pancreatic Cancer Borderline
Pancreatic Cancer Resectable
Intervention:
COMBINATION_PRODUCT: ASP-1929 photoimmunotherapy
A...